Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
Stopped early · Phase 1
Conditions studied: Pancreatic Cancer
In brief
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA. Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating patients with stage I, stage II, or stage III pancreatic cancer that has been surgically removed.
Key facts
- Study ID
- NCT00003434
- Run by
- Duke University
- People needed
- 8
- Starts
- 1998-06-01
- Expected to finish
- 2002-08-01
- Last updated by the study team
- 2014-02-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.